Treatment Changes Study Sample Clauses

Treatment Changes Study. The patients in the treatment changes study all met the 1987 ACR criteria for RA and were attending outpatient departments in South East London in either a large teaching hospital or a district general hospital. Patients were consecutive attendees at the rheumatology departments in each hospital. This was a cross-sectional study with data collected over a two year span. Patients were receiving routine clinical care. Healthcare Professionals Focus Group N=6 KCH and Southwark PCT RA Patient Focus Group 2 N=5 KCH RA Patient Focus Group 1 N=6 KCH Figure 2:1 Summary Of Participants’ Included In The Study IDENTIFYING LIMITATIONS OF CURRENT CARE GP Individual Interviews N=13 Lambeth PCT, Southwark PCT, Lewisham PCT Secondary Care Healthcare Professional Individual Interviews N=15 KCH, XXX, GSTT RA Patients Individual Interviews N=26 KCH, XXX Carers N=11 KCH, XXX Standards of Care Survey and Initial Satisfaction survey (Tijhuis) N=100 KCH Second Satisfaction Survey (Hill) N=100 KCH Patient Group Survey N=60 KCH FATIGUE IN RA Clinical Association Studies Initial Fatigue Association Study N=238 KCH Alternative Measure Fatigue Study N=274 KCH, XXX Treatment Effects Study Early RA N=395* ERAN Network Established RA N=84 KCH Fatigue Measurements Study RA Patients N=105§ KCH FIBROMYALGIC RA AND PAIN THRESHOLDS IN RA Initial Fibromyalgic RA and Pain Threshold Study N=105§ KCH Replicate Fibromyalgic RA Study in Established RA N=321 KCH, XXX, GSTT, Woolwich Replicate Fibromyalgic RA Study in Early RA N=395* ERAN network UNDERSTANDING TREATMENT DECISIONS Temporal Changes Study N=987 (1997 – 202; 2003 – 300; 2006 – 105; 2008 – 71; 2010 – 309) KCH, XXX Treatment Changes Study N=482 KCH, XXX * This represents the same group of patients § This represents the same group of patients KCH – King’s College Hospital; XXX – University Hospital Lewisham; GSTT – Guy’s and St Thomas’s Trust; Woolwich – Woolwich Hospital ERAN Network – A network of British rheumatology departments who collect & monitor clinical details on all early RA patients in a standard way in order to assess outcome in the long term on a national basis.
Sample 1
AutoNDA by SimpleDocs
Treatment Changes Study. Data analysis was done by the Statistical Package for the Social Sciences (SPSS for Windows 16). Simple descriptive analyses were applied to all data. Patients were divided by DAS28 categories into four groups: Remission (DAS28<2.6), low disease activity (DAS28 2.6 to <3.2), moderate disease activity (DAS28 3.2 to <5.1) and high disease activity (DAS28 ≥5.1). For each category the percentage of patients who had a treatment change was calculated. In those with high disease activity (DAS28≥5.1) the rate of treatment change was examined further and patients were divided further into five groups according to DAS28. These groups comprised DAS28 of 5.1-5.5, DAS28 of 5.5 to 6.0, DAS28 of 6.0-6.5, DAS28 of 6.5-7.0 and those with a DAS28 of over 7.0. Again percentages of patients who had a treatment change were calculated for each group. The percentage for each type of treatment change was also calculated for each DAS28 category. To determine what influenced treatment changes binary regression was performed for each variable (univariate analysis) and reported as odds ratios (as there were categorical and continuous variables). Any variable which showed significance (p≤0.05) at this level was carried forward into the multivariate analysis and the odds ratios are reported. Two models were analysed, firstly DAS28 was used as a measure of disease activity and its constituents were excluded. In the second model the four constituents of the DAS28 (tender joint count, swollen joint count, ESR and patient global assessment) were included and the DAS28 composite measure was excluded. Patients were categorised as fibromyalgic and non-fibromyalgic RA (Tender minus swollen joint counts) to explore the effect of fibromyalgic RA on treatment decisions, patients were grouped into fibromyalgic and non-fibromyalgic RA. Chi- squared testing was then used to determine any if there were differences between groups in treatment changes and also the kind of treatment change that was initiated. To explore the effect of age on treatment decisions, patients were placed into three categories; under 45 years, 45-65 years and over 65 years. The effect of age of onset on treatments decisions was also explored: patients were again placed into three categories depending on age at onset of disease; under 45 years, 45-65 years and over 65 years at onset of disease. Chi-squared testing was then used to determine any if there were differences between groups in treatment changes and also the kind of t...
Sample 1

Related to Treatment Changes Study

  • Agreement Changes The Company reserves the right to change the terms of this Agreement and the Plan without your consent to the extent necessary or desirable to comply with the requirements of Code section 409A, the Treasury regulations and other guidance thereunder.

  • Amendments - Changes/Extra Work The Subrecipient shall make no changes to this Contract without the County’s written consent. In the event that there are new or unforeseen requirements, the County has the discretion with the Subrecipient’s concurrence, to make changes at any time without changing the scope or price of the Contract.‌ If County-initiated changes or changes in laws or government regulations affect price, the Subrecipient’s ability to deliver services, or the project schedule, the Subrecipient will give County written notice no later ten (10) days from the date the law or regulation went into effect or the date the change was proposed and Subrecipient was notified of the change. Such changes shall be agreed to in writing and incorporated into a Contract amendment. Said amendment shall be issued by the County-assigned Contract Administrator, shall require the mutual consent of all Parties, and may be subject to approval by the County Board of Supervisors. Nothing herein shall prohibit the Subrecipient from proceeding with the work as originally set forth or as previously amended in this Contract.

  • Product Changes Vocera shall have the right, in its absolute discretion, without liability to End User, to update to provide new functionality or otherwise change the design of any Product or to discontinue the manufacture or sale of any Product. Vocera shall notify End User at least 90 days prior to the delivery of any Product which incorporates a change that adversely affects form, fit or function (“Material Change”). Vocera shall also notify End User at least 90 days prior to the discontinuance of manufacture of any Product. Notification will be made as soon as reasonably practical for changes associated with regulatory or health and safety issues.

  • CONSISTENT CHANGES The Existing Loan Documents are hereby amended wherever necessary to reflect the changes described above.

  • Treatment of Unallowable Costs Previously Submitted for Payment The Debtors further agree that within 90 days of the Effective Date of this Agreement they shall identify to applicable Medicare and TRICARE fiscal intermediaries, carriers, and/or contractors, and Medicaid and FEHBP fiscal agents, any Unallowable Costs (as defined in this Paragraph) included in payments previously sought from the United States, or any State Medicaid program, including, but not limited to, payments sought in any cost reports, cost statements, information reports, or payment requests already submitted by the Debtors or any of their current subsidiaries or affiliates, and shall request, and agree, that such cost reports, cost statements, information reports, or payment requests, even if already settled, be adjusted to account for the effect of the inclusion of the Unallowable Costs. The Debtors agree that the United States, at a minimum, shall be entitled to recoup from the Debtors any overpayment plus applicable interest and penalties as a result of the inclusion of such Unallowable Costs on previously-submitted cost reports, information reports, cost statements, or requests for payment. Any payments due after the adjustments have been made shall be paid to the United States pursuant to the direction of the Department of Justice and/or the affected agencies. The United States reserves its rights to disagree with any calculations submitted by the Debtors or any of their current subsidiaries or affiliates on the effect of inclusion of Unallowable Costs (as defined in this Paragraph) on the Debtors or any of their current subsidiaries or affiliates’ cost reports, cost statements, or information reports.

  • Program Changes Contractor agrees to inform the County of any alteration in program or service delivery at least thirty (30) days prior to the implementation of the change, or as soon as reasonably feasible.

  • Future Treatment of Unallowable Costs Unallowable Costs shall be separately determined and accounted for by Xx. Xxxxxxx, and Xx. Xxxxxxx shall not charge such Unallowable Costs directly or indirectly to any contracts with the United States or any State Medicaid program, or seek payment for such Unallowable Costs through any cost report, cost statement, information statement, or payment request submitted by Xx. Xxxxxxx or any of its subsidiaries or affiliates to the Medicare, Medicaid, TRICARE, or FEHBP Programs.

  • Account Changes Neither the Financial Institution nor the Grantor will change the name or account number of a Collateral Account without the consent of the Secured Party. The Financial Institution will promptly notify the Servicer of any changes. This Agreement will apply to each successor account to a Collateral Account, which will also be a Collateral Account.

  • RESTOCKING (EXCHANGES AND RETURNS) There will be no restocking charge to the Customer for return or exchange of any item purchased under the terms of any award. If the Customer wishes to return items purchased under an awarded contract, the Contractor agrees to exchange, these items for other items, with no additional charge incurred. Items must be returned to Contractor within thirty (30) days from date of delivery. If there is a difference in price in the items exchanged, the Contractor must notify H-GAC and invoice Customer for increase price or provide the Customer with a credit or refund for any decrease in price per Customer’s preference. On items returned, a credit or cash refund will be issued by the Contractor to Customer. This return and exchange option will extend for thirty (30) days following the expiration of the term of the Contract. All items returned by the Customer must be unused and in the same merchantable condition as when received. Items that are special ordered may be returned only upon approval of the Contractor.

  • QUANTITY CHANGES PRIOR TO AWARD The Commissioner reserves the right, at any time prior to the award of a specific quantity Contract, to alter in good faith the quantities listed in the Bid Specifications. In the event such right is exercised, the lowest responsible Bidder meeting Bid Specifications will be advised of the revised quantities and afforded an opportunity to extend or reduce its Bid price in relation to the changed quantities. Refusal by the low Bidder to so extend or reduce its Bid price may result in the rejection of its Bid and the award of such Contract to the lowest responsible Bidder who accepts the revised qualifications.

Time is Money Join Law Insider Premium to draft better contracts faster.